Lukas Weseslindtner

Dr. Lukas Weseslindtner

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Clinical Virology
Verified
Journal Article
Open access
LWLisa Weidner
Lisa Weidner
SGSimon Gänsdorfer
Simon Gänsdorfer
SUStephan Unterweger
Stephan Unterweger
LWLukas Weseslindtner
Lukas Weseslindtner
CDCamilla Drexler
Camilla Drexler
CJChristof Jungbauer
Christof Jungbauer
Since the emergence of SARS-CoV-2 numerous antibody assays have become available, demonstrating different performance characteristics. This study focused on a quantitative correlation between different commercial assays and a neutralization test (NT). Comparative data is needed as a basis for the production of convalescent plasma and potential interpretations COVID-19 immunity.

5 October 2014 in AGE
Verified
Journal Article
Closed access
PDF file
MHMats Haloschan
Mats Haloschan
RBRainer Bettesch
Rainer Bettesch
IGIrene Görzer
Irene Görzer
LWLukas Weseslindtner
Lukas Weseslindtner
MKMichael Kundi
Michael Kundi
EPElisabeth Puchhammer-Stöckl
Elisabeth Puchhammer-Stöckl

30 May 2020 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MTMarianna Traugott
Marianna Traugott
SAStephan Walter Aberle
Stephan Walter Aberle
JAJudith Helene Aberle
Judith Helene Aberle
HGHannah Griebler
Hannah Griebler
MKMario Karolyi
Mario Karolyi
LWLukas Weseslindtner
Lukas Weseslindtner
We comparatively assessed sensitivities and specificities of 4 commercial enzyme-linked immunosorbent assays (ELISAs) and 2 rapid tests in 77 patients with polymerase chain reaction–confirmed severe acute respiratory syndrome coronavirus 2 infection, grouped by interval since symptom onset. Although test sensitivities were low (80% between days 6 and 10 after symptom onset. The evaluated tests (including IgG and rapid tests) provided positive results in all patients at or after the 11th day after onset of disease. The specificities of the ELISAs were 83% (IgA), 98% (IgG), and 97% (IgM and total antibody).

1 May 2006 in Journal of Clinical Virology
Verified
Journal Article
Closed access
JAJudith H. Aberle
Judith H. Aberle
EFElisabeth Formann
Elisabeth Formann
PSPetra Steindl-Munda
Petra Steindl-Munda
LWLukas Weseslindtner
Lukas Weseslindtner
CGCalin Gurguta
Calin Gurguta
HHHeidemarie Holzmann
Heidemarie Holzmann

30 April 2012 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
LWLukas Weseslindtner
Lukas Weseslindtner
HKH. Kerschner
H. Kerschner
DSD. Steinacher
D. Steinacher
RNRaffael Nachbagauer
Raffael Nachbagauer
MKM. Kundi
M. Kundi
EPE. Puchhammer-Stöckl
E. Puchhammer-Stöckl
In lung transplant recipients (LuTRs), human cytomegalovirus (HCMV) DNAemia may be associated with HCMV disease and reduced survival of the allograft. Because T cells are essential for controlling HCMV replication, we investigated in this prospective study whether the kinetics of plasma HCMV DNA loads in LuTRs are associated with HCMV‐specific CD8+ T cell responses, which were longitudinally assessed using a standardized assay. Sixty‐seven LuTRs were monitored during the first year posttransplantation, with a mean of 17 HCMV DNA PCR quantifications and 11.5 CD8+ T cell tests performed per patient. HCMV‐specific CD8+ T cell responses displayed variable kinetics in different patients, differed significantly before the onset of HCMV DNAemia in LuTRs who subsequently experienced episodes of DNAemia with high (>1000 copies/mL) and low plasma DNA levels (p = 0.0046, Fisher's exact test), and were absent before HCMV disease. In HCMV‐seropositive LuTRs, high‐level DNAemia requiring preemptive therapy occurred more frequently when HCMV‐specific CD8+ T cell responses fluctuated, were detected only after HCMV DNA detection, or remained undetectable (p = 0.0392, Fisher's exact test). Thus, our data indicate that HCMV‐specific CD8+ T cells influence the magnitude of HCMV DNAemia episodes, and we propose that a standardized measurement of CD8+ T cell immunity might contribute to monitoring the immune status of LuTRs posttransplantation.

14 February 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
MGMarianne Graninger
Marianne Graninger
CJClaudia Maria Jani
Claudia Maria Jani
ERElisabeth Reuberger
Elisabeth Reuberger
KPKatja Prüger
Katja Prüger
PGPhilipp Gaspar
Philipp Gaspar
LWLukas Weseslindtner
Lukas Weseslindtner
While the measurement of neutralizing antibodies is considered a valuable tool in assessing protection against SARS-CoV-2, neutralization tests employ live-virus isolates and cell culture, requiring advanced laboratory biosafety levels. Including a large sample panel (over 700 samples), this study provides adapted cutoff values calculated for seven commercial immunoassays (including four surrogate neutralization assays and a protein-based microarray) that robustly correlate with specific titers of neutralizing antibodies.